Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Quarterly Earnings Results, Beats Estimates By $0.58 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) released its quarterly earnings results on Wednesday. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58, Briefing.com reports. The firm had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter last year, the business earned ($0.54) earnings per share.

Day One Biopharmaceuticals Trading Down 0.3 %

Shares of NASDAQ DAWN traded down $0.05 during trading hours on Friday, reaching $14.67. The stock had a trading volume of 451,279 shares, compared to its average volume of 933,716. Day One Biopharmaceuticals has a 52-week low of $10.90 and a 52-week high of $18.07. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -14.29 and a beta of -1.51. The business’s fifty day moving average price is $14.18 and its two-hundred day moving average price is $14.39.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 3,202 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $44,828.00. Following the transaction, the general counsel now owns 26,928 shares in the company, valued at approximately $376,992. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, General Counsel Adam Dubow sold 3,202 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the sale, the general counsel now owns 26,928 shares of the company’s stock, valued at approximately $376,992. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Samuel C. Blackman sold 2,232 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares in the company, valued at approximately $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,748 shares of company stock valued at $689,072 in the last ninety days. Corporate insiders own 8.40% of the company’s stock.

Analysts Set New Price Targets

DAWN has been the topic of several research reports. Piper Sandler reissued an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and lifted their target price for the company from $11.00 to $24.00 in a research report on Thursday, August 1st. JPMorgan Chase & Co. cut their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.